Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns
Regenxbio's gene therapy faces market challenges as Goldman Sachs lowers its rating and price target, citing competition and ...
EuropaWire6h
Patients as Partners® Europe Launches the 9th Annual Event with 2025 Keynotes, Featured Speakers and Topics
The Conference Forum has announced the 9th annual Patients as Partners® Europe event, scheduled for May 20-21, 2025, at the Royal National Hotel ...
Deutsche Bank sets Sarepta stock target at $136, cites risks
Deutsche Bank (ETR:DBKGn) initiated coverage of Sarepta Therapeutics (NASDAQ:SRPT), assigning a Hold rating to the ...
Sarepta initiated with a Hold at Deutsche Bank
Deutsche Bank analyst David Hoang initiated coverage of Sarepta (SRPT) with a Hold rating and $136 price target Maximize Your Portfolio with ...